MXPA04004919A - Uso de nanoparticulas inorganicas sinteticas como vehiculos para farmacos oftalmicos y oticos. - Google Patents

Uso de nanoparticulas inorganicas sinteticas como vehiculos para farmacos oftalmicos y oticos.

Info

Publication number
MXPA04004919A
MXPA04004919A MXPA04004919A MXPA04004919A MXPA04004919A MX PA04004919 A MXPA04004919 A MX PA04004919A MX PA04004919 A MXPA04004919 A MX PA04004919A MX PA04004919 A MXPA04004919 A MX PA04004919A MX PA04004919 A MXPA04004919 A MX PA04004919A
Authority
MX
Mexico
Prior art keywords
ophthalmic
carriers
compositions
nanoparticles
inorganic nanoparticles
Prior art date
Application number
MXPA04004919A
Other languages
English (en)
Inventor
L Meadows David
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of MXPA04004919A publication Critical patent/MXPA04004919A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)

Abstract

Se describe el uso de nanoparticulas de materiales inorganicos (por ejemplo, arcillas de esmectita sintetica) en composiciones farmaceuticas oftalmicas y oticas. Las nanoparticulas son utilizadas como vehiculos o depositos biologicamente inertes para farmacos oftalmicos y oticos. Las nanoparticulas pueden tambien ser utilizadas para modificar las propiedades reologicas de las composiciones para incrementar la viscosidad o las caracteristicas de flujo de las composiciones y/o para incrementar el tiempo de retencion de las composiciones en el ojo o en el oido.
MXPA04004919A 2001-12-21 2002-12-20 Uso de nanoparticulas inorganicas sinteticas como vehiculos para farmacos oftalmicos y oticos. MXPA04004919A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34298301P 2001-12-21 2001-12-21
PCT/US2002/041248 WO2003059194A2 (en) 2001-12-21 2002-12-20 Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs

Publications (1)

Publication Number Publication Date
MXPA04004919A true MXPA04004919A (es) 2004-08-11

Family

ID=23344163

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004919A MXPA04004919A (es) 2001-12-21 2002-12-20 Uso de nanoparticulas inorganicas sinteticas como vehiculos para farmacos oftalmicos y oticos.

Country Status (19)

Country Link
US (2) US20050003014A1 (es)
EP (1) EP1474109B1 (es)
JP (1) JP2005514429A (es)
KR (1) KR100990810B1 (es)
CN (1) CN100441169C (es)
AT (1) ATE478657T1 (es)
AU (1) AU2002367029B2 (es)
BR (1) BR0215238A (es)
CA (1) CA2467763C (es)
DE (1) DE60237475D1 (es)
DK (1) DK1474109T3 (es)
ES (1) ES2349235T3 (es)
HK (1) HK1075001A1 (es)
MX (1) MXPA04004919A (es)
PL (1) PL211494B1 (es)
PT (1) PT1474109E (es)
SI (1) SI1474109T1 (es)
WO (1) WO2003059194A2 (es)
ZA (1) ZA200403666B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1474109T1 (sl) 2001-12-21 2010-11-30 Alcon Inc Uporaba sintetičnih anorganskih nanodelcev kot nosilcev za oftalmična zdravila
WO2003059193A2 (en) * 2001-12-21 2003-07-24 Alcon, Inc. Use of nanoparticles as carriers for biocides in ophthalmic compositions
CA2467764A1 (en) * 2001-12-21 2003-07-24 Alcon, Inc. Inorganic nanoparticles to modify the viscosity and physical properties of ophthalmic and otic compositions.
WO2004066975A1 (en) 2002-12-18 2004-08-12 Hough Ear Institute Otologic nanotechnology
US7723311B2 (en) 2003-06-18 2010-05-25 Nanobiomagnetics, Inc. Delivery of bioactive substances to target cells
US8651113B2 (en) 2003-06-18 2014-02-18 Swr&D Inc. Magnetically responsive nanoparticle therapeutic constructs and methods of making and using
US7344491B1 (en) 2003-11-26 2008-03-18 Nanobiomagnetics, Inc. Method and apparatus for improving hearing
EP2112196A1 (en) * 2008-04-25 2009-10-28 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO A liquid composition comprising polymer chains and particles of an inorganic material in a liquid
US20100098768A1 (en) * 2008-10-16 2010-04-22 Clarkson University Method of neuroprotection from oxidant injury using metal oxide nanoparticles
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
JP6343147B2 (ja) 2010-08-30 2018-06-13 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 狭窄病変および血栓溶解療法のための剪断による制御放出
CN104531812A (zh) 2010-10-01 2015-04-22 现代治疗公司 设计核酸及其使用方法
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES2911677T3 (es) 2011-10-03 2022-05-20 Modernatx Inc Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
RS63244B1 (sr) 2011-12-16 2022-06-30 Modernatx Inc Kompozicije modifikovane mrna
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US20140010861A1 (en) 2012-04-02 2014-01-09 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
CA2868391A1 (en) 2012-04-02 2013-10-10 Stephane Bancel Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
KR101415221B1 (ko) * 2012-08-07 2014-07-09 한국표준과학연구원 무기 나노입자를 유효성분으로 함유하는 혈관 신생 관련 질환의 예방 및 치료용 조성물
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
JP2016530294A (ja) 2013-09-03 2016-09-29 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． キメラポリヌクレオチド
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
CL2013003807A1 (es) * 2013-12-31 2014-07-11 Univ Santiago Chile Dispositivos de tubos pequeños de silicona que contienen nanopartículas y micropartículas de zeolitas como agentes de liberación prolongada y controlada, cargadas con 2-metoxiestradiol y suspendidas en un medio oleoso que también contiene 2-metoxiestradiol.
CA2955250A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3171895A1 (en) 2014-07-23 2017-05-31 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
JP6567648B2 (ja) 2014-07-28 2019-08-28 サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッドＳｕｎ Ｐｈａｒｍａ Ａｄｖａｎｃｅｄ Ｒｅｓｅａｒｃｈ Ｃｏｍｐａｎｙ Ｌｉｍｉｔｅｄ 薬物のバイオアベイラビリティーの増加および／または眼作用の持続方法
NZ737726A (en) 2015-07-06 2023-03-31 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
KR101748120B1 (ko) * 2015-07-13 2017-06-16 서울대학교산학협력단 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도
HRP20220525T1 (hr) 2015-12-23 2022-05-27 Modernatx, Inc. Postupci uporabe polinukleotida koji kodiraju ligand ox40
EP3400023A1 (en) 2016-01-10 2018-11-14 ModernaTX, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
US11077051B2 (en) 2016-09-15 2021-08-03 University of Pittsburgh—of the Commonwealth System of Higher Education Shear-thinning therapeutic composition, and related methods
EP3625246A1 (en) 2017-05-18 2020-03-25 ModernaTX, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
NZ760232A (en) 2017-06-07 2023-05-26 Regeneron Pharma Compositions and methods for internalizing enzymes
KR20200118151A (ko) 2018-02-07 2020-10-14 리제너론 파마슈티칼스 인코포레이티드 치료 단백질 전달을 위한 방법 및 조성물
CN109045305B (zh) * 2018-07-31 2021-12-10 东华大学 一种tpgs修饰的锂皂石纳米颗粒的制备方法
US20220133908A1 (en) 2019-02-08 2022-05-05 Curevac Ag Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
EP3851097A1 (en) * 2020-01-15 2021-07-21 Universidad De Zaragoza Controlled release formulations
EP4172194A1 (en) 2020-07-31 2023-05-03 CureVac SE Nucleic acid encoded antibody mixtures
WO2022059736A1 (ja) 2020-09-17 2022-03-24 株式会社レストアビジョン 小胞体ストレスまたはオールトランスレチナールに関連する疾患、障害または症状を治療または予防するため、または網膜厚を保護し、または網膜厚の萎縮もしくは萎縮進行を抑制するための組成物。
KR20230088732A (ko) 2020-09-29 2023-06-20 옥스포드 유니버시티 이노베이션 리미티드 뇌졸중 치료
TW202346348A (zh) 2022-01-10 2023-12-01 美商再生元醫藥公司 作為基因治療所遞送之bbb靶向的gaa在龐貝氏症小鼠模型中治療cns及肌肉
WO2023220603A1 (en) 2022-05-09 2023-11-16 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
US20240182561A1 (en) 2022-11-04 2024-06-06 Regeneron Pharmaceuticals, Inc. Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
WO2024107765A2 (en) 2022-11-14 2024-05-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US627124A (en) * 1899-06-20 Fan attachment for sewing-machines
US3947573A (en) 1969-12-01 1976-03-30 Burton, Parsons And Company, Inc. Opthalmic solution
US3884826A (en) * 1973-07-20 1975-05-20 Barnes Hind Pharm Inc Thixotropic cleaning agent for hard contact lenses
US3974125A (en) * 1974-09-27 1976-08-10 Exxon Research And Engineering Company Higher dialkyl dimethyl ammonium clay gelling agents for unsaturated polyester compositions
US4127423A (en) * 1977-09-13 1978-11-28 Burton, Parsons And Company, Inc. Contact lens cleaning solution
US4120949A (en) 1977-10-05 1978-10-17 Cooper Laboratories, Inc. Ophthalmic solution
US4271143A (en) * 1978-01-25 1981-06-02 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4394179A (en) * 1979-06-25 1983-07-19 Polymer Technology Corporation Abrasive-containing contact lens cleaning materials
US4374745A (en) * 1981-08-13 1983-02-22 Barnes-Hind Pharmaceuticals, Inc. Cleaning compositions
US4940701A (en) * 1984-01-25 1990-07-10 Beecham Group P.L.C. Topical drug release system
GB8401965D0 (en) * 1984-01-25 1984-02-29 Beecham Group Plc Composition
EP0217440A1 (en) * 1985-09-27 1987-04-08 The Procter & Gamble Company Stable aqueous pharmaceutical suspensions
US4738851A (en) * 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US4804539A (en) * 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
IL80298A (en) 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
WO1988004168A1 (en) * 1986-12-08 1988-06-16 Arseco, Inc. A storage stable topical composition
US4847078A (en) * 1987-01-14 1989-07-11 Arseco, Inc. Storage stable topical composition having moisture control agent
BR8707615A (pt) 1986-12-24 1989-10-03 Alcon Lab Inc Composicao para limpeza de lentes de contato e processo para sua utilizacao
US4891043A (en) * 1987-05-28 1990-01-02 Board Of Trustees Of The University Of Illinois System for selective release of liposome encapsulated material via laser radiation
US4923699A (en) * 1988-06-03 1990-05-08 Kaufman Herbert E Eye treatment suspension
US5037647A (en) * 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
US5674504A (en) * 1989-07-12 1997-10-07 L'oreal Cosmetic composition in the form of an aqueous gel containing in suspension spheroids of a non-hydrophilic, lipoidal substance
US5185152A (en) * 1990-01-10 1993-02-09 Peyman Gholam A Method and apparatus for controlled release drug delivery to the cornea and anterior chamber of the eye
CA2064160C (en) * 1991-03-27 1998-08-11 Paul J. T. Missel Use of combinations of gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5212162A (en) * 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
EP0546728A3 (en) * 1991-12-13 1993-09-08 Alcon Laboratories Inc Physiological tear compositions and methods for their preparation
US5139782A (en) * 1991-12-23 1992-08-18 Uop Facial cleansing mineral compositions
US5505953A (en) * 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
ES2221921T3 (es) * 1992-07-13 2005-01-16 Shiseido Company, Ltd. Composicion para preparacion dermatologica.
US5532224A (en) * 1993-12-22 1996-07-02 Alcon Laboratories, Inc. Contact lens cleaning composition containing polyalklene oxide modified siloxanes
AU3070395A (en) * 1994-07-22 1996-02-22 Alcon Laboratories, Inc. Use of low molecular weight amino acids in ophthalmic compositions
US5585108A (en) * 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
ES2238702T3 (es) * 1995-12-21 2005-09-01 Alcon Laboratories, Inc. Utilizacion de ciertos compuestos de isoquinolinsulfonilo en el tratamiento de glaucomas y de isquemias oculares.
JP3736916B2 (ja) 1996-02-19 2006-01-18 株式会社サンコンタクトレンズ 含水性ソフトコンタクトレンズの消毒用組成物とその用途
US6015816A (en) 1996-02-29 2000-01-18 The Research Foundation Of State University Of New York Antimicrobial compositions
WO1998011875A1 (en) * 1996-09-20 1998-03-26 Bausch & Lomb Incorporated Method and composition for rewetting contact lenses and relieving eye dryness
US5811580A (en) * 1996-12-04 1998-09-22 The Lubrizol Corporation Process for the preparation of N-hydrocarbyl-substituted amides via the ritter reaction using solid clay catalysts
WO1998025649A1 (en) * 1996-12-13 1998-06-18 Alcon Laboratories, Inc. Use of low molecular weight amino alcohols in ophthalmic compositions
US5858346A (en) * 1997-05-09 1999-01-12 Allergan Compositions and methods for enhancing contact lens wearability
ES2302881T3 (es) * 1997-07-29 2008-08-01 Alcon Laboratories, Inc. Composiciones oftalmicas que contienen polimeros de galactomanana y borato.
CA2306127A1 (en) 1997-11-12 1999-09-02 Bausch & Lomb Incorporated Treatment of contact lenses with aqueous solution comprising an alkali carbonate
ZA9811445B (en) 1997-12-19 1999-08-16 Alcon Lab Inc Aminobiguanides and the use thereof to disinfect contact lenses and preserve pharmaceutical compositions.
JPH11281937A (ja) * 1998-03-27 1999-10-15 Menicon Co Ltd コンタクトレンズ用剤
US20010016577A1 (en) * 1998-08-24 2001-08-23 Douglas Joseph Dobrozsi Oral mucoadhesive compositions containing gastrointestinal actives
US6319513B1 (en) * 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
FR2783419B1 (fr) 1998-09-18 2002-07-12 Oreal Utilisation a ph acide de silicates mixtes en tant qu'agents tenseurs dans des compositions cosmetiques anti-rides
CA2361421A1 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6333054B1 (en) * 1999-10-21 2001-12-25 Amuchina S.P.A. Topical, non-cytotoxic, antimicrobial hydrogel with thixotropic properties
JP2001240547A (ja) * 2000-02-29 2001-09-04 Lion Corp 花粉症抑制剤
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US20040076682A1 (en) * 2001-02-15 2004-04-22 Toshiyuki Kohzaki Novel ophthalmic compositions
AU2002246868B2 (en) 2001-08-02 2007-05-31 Johnson & Johnson Vision Care, Inc. Antimicrobial lenses and methods of their use
SI1474109T1 (sl) 2001-12-21 2010-11-30 Alcon Inc Uporaba sintetičnih anorganskih nanodelcev kot nosilcev za oftalmična zdravila
CA2467764A1 (en) * 2001-12-21 2003-07-24 Alcon, Inc. Inorganic nanoparticles to modify the viscosity and physical properties of ophthalmic and otic compositions.
US7217853B2 (en) * 2002-05-24 2007-05-15 Corium International, Inc. Composition for cushions, wound dressings and other skin-contacting products
JP4448441B2 (ja) * 2002-06-05 2010-04-07 ユニヴァーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイテッド 眼科用医薬のデリバリーシステム
US20050181015A1 (en) * 2004-02-12 2005-08-18 Sheng-Ping (Samuel) Zhong Layered silicate nanoparticles for controlled delivery of therapeutic agents from medical articles
US20060193787A1 (en) * 2005-01-31 2006-08-31 Si-Shen Feng Nanoparticle-based drug delivery system

Also Published As

Publication number Publication date
PL374262A1 (en) 2005-10-03
ZA200403666B (en) 2005-07-27
EP1474109A4 (en) 2006-03-29
EP1474109A2 (en) 2004-11-10
CN100441169C (zh) 2008-12-10
US8257745B2 (en) 2012-09-04
AU2002367029B2 (en) 2008-10-02
DE60237475D1 (de) 2010-10-07
DK1474109T3 (da) 2010-10-25
ES2349235T3 (es) 2010-12-29
PL211494B1 (pl) 2012-05-31
CA2467763A1 (en) 2003-07-24
BR0215238A (pt) 2005-05-31
CN1604770A (zh) 2005-04-06
WO2003059194A2 (en) 2003-07-24
KR100990810B1 (ko) 2010-10-29
SI1474109T1 (sl) 2010-11-30
ATE478657T1 (de) 2010-09-15
WO2003059194A3 (en) 2004-05-13
AU2002367029A1 (en) 2003-07-30
EP1474109B1 (en) 2010-08-25
PT1474109E (pt) 2010-10-25
US20050003014A1 (en) 2005-01-06
HK1075001A1 (en) 2005-12-02
JP2005514429A (ja) 2005-05-19
KR20040072669A (ko) 2004-08-18
US20110274760A1 (en) 2011-11-10
CA2467763C (en) 2011-09-13

Similar Documents

Publication Publication Date Title
HK1075001A1 (en) Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs
MXPA04005227A (es) Uso de nanoparticulas como portadores para biocidas en composiciones oftalmicas.
DE60231682D1 (de) Naturkautschuk-Masterbatch dessen Herstellungsverfahren, und Naturkautschukzusammensetzung
BRPI0507680A (pt) partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas
BR0106238A (pt) Massa para moldagem com boa capacidade de moldagem por sopro
DE60232660D1 (de) Humane dr4-antikörper und deren anwendungen
BG64475B1 (bg) Ципразидонови соли
DK1227529T3 (da) Elektroluminescerende indretninger
FR2712812B1 (fr) Composition pour la production de produits thérapeutiques in vivo.
CY1105953T1 (el) Συνθεσεις για απελευθερωση συνδυασμων φαρμακων
EA200400148A1 (ru) Стабилизированная суспензионная лекарственная форма для перорального применения
BR0208741A (pt) Derivados de piperidina
EP1579846A3 (en) Personal care product
AR036199A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas
ATE448769T1 (de) Abgabe von hydrogel-zusammensetzungen aus feinsprühnebel
YU13301A (sh) Muskarinski agonisti i antagonisti
HK1097188A1 (en) Alginate viscoelastic composition, method of use and package
AU2003900335A0 (en) Microparticles for selectively targeted hyperthermia
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
AU2001251655A1 (en) Cytokine uses; compositions; methods
ATE272642T1 (de) Thieno(2,3-d)pyrimidindione und ihre verwendung als pharmazeutische mittel
NO20022739D0 (no) Nye terapeutiske kombinasjoner av (S)-2-(benzylamino-metyl)- 2,3,8,9-tetrahydro-7H-1,4-dioksino[2,3-e]indol-8-on ognevroleptika for behandling eller forhindring av psykotiskelidelser
AU7533394A (en) Antiacid pharmaceutical composition in the form of a suspension based on sucralphate gel
JP2002201126A5 (es)
AU2003290603A1 (en) Method of making, and the use of cytotoxic agents containing elemental selenium

Legal Events

Date Code Title Description
FG Grant or registration